In the recent studies, the NSAID, 5-aminosalicylic acid (5-ASA) was reported to inhibit TGFβ signaling by blocking phosphorylated Smad2/3 to enter the nucleus in colorectal cancer cells [35]; and tolfenamic acid was found to inhibit the phosphorylation of Smad2/3 by interacting with the MAP kinase pathway [36]. Here, SMAD2 is linked to colorectal cancer.